The Latest Cardiac and Vascular News
SUZHOU, China, Aug. 1, 2023 /PRNewswire/ — Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced on July 31, 2023 that the first Chinese patient of the multi-center registration clinical trial for TaurusTrio™ Transcatheter Aortic Valve Replacement (TAVR) system has been enrolled. TaurusTrio™ is […]
SUZHOU, China, Nov. 25, 2022 /PRNewswire/ — inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrential Tricuspid Regurgitation. The Trans-Jugular TTVR procedure was performed on November 21, 2022, on compassionate grounds […]
SUZHOU, China, Jan. 19, 2022 /PRNewswire/ — Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and will commit additional capital based upon development milestones in […]
SUZHOU, China, Dec. 30, 2021 /PRNewswire/ — On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“TSMVR”) technology was successfully carried out in Asia. The implantation of Peijia’s Highlife TSMVR system was performed by Professor Mao Chen and his team of West China Medical Center of Sichuan University as part of a research clinical […]
SUZHOU, China, Sept. 14, 2021 /PRNewswire/ — Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the third-generation transcatheter aortic valve (“TAVR”) system, following the first successful patient implant in Zhongshan Hospital of Fudan University. Led by Professor Ge Junbo, the procedure was completed successfully with support from the […]
To Advise the Company’s Mitral Transcatheter Edge-to-edge Repair Project and the Company in General SUZHOU, China, Sept. 6, 2021 /PRNewswire/ — Peijia Medical Limited (HKEX: 9996) is pleased to announce Saibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter […]
– Peijia Medical takes China into the “Recoverable Era” with its TAVR products featuring a second-generation transcatheter aortic valve replacement system approved for commercialization SUZHOU, China , June 28, 2021 / PRNewswire / – The TaurusElite ® Transcatheter Aortic Valve Replacement System (hereinafter referred to as “TaurusElite ® “) and which has been developed by Peijia Medical (9996. HK) It […]
SUZHOU, China, June 24, 2021 /PRNewswire/ — On June 15, 2021, Jasper® SS—a new detachable coil independently developed by Achieva Medical, subsidiary of Peijia Medical (9996.HK)—was approved by the National Medical Products Administration (“NMPA”) for commercialization (registration number GXZZ 20113130440). In the field of neurointervention, embolization coils are designed to be as thin as […]
SUZHOU, China, June 9, 2021 /PRNewswire/ — Peijia Medical (HKEX:9996, or “Peijia“), a leading player in China for medical technology, announced a partnership with inQB8, a Boston based medical technology incubator, to explore innovative solutions for Structural Heart Disease. This partnership includes Peijia’s acquisition of a transcatheter tricuspid replacement technology (“TTVR”, or “inQB8 TTVR”) from inQB8, which is currently in […]
SUZHOU, China, June 4, 2021 /PRNewswire/ — Peijia Medical Limited signed a memorandum of strategic cooperation with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. on June 2. Going forward, the two parties will collaborate intensively on the commercialization of TAVR products, ultimately providing more Chinese medical staff and patients with better quality […]
